Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classifica tra le azioni #4535
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$27.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
-1.41%
Variazione (1 anno)
197.05%
Paese
US
Scambia Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
EPS per Tango Therapeutics, Inc. (TNGX)
EPS al June 2026 TTM: $-0.85
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Tango Therapeutics, Inc., l’EPS attuale della società (TTM) è $-0.85. Alla fine del 2023, la società aveva un EPS di $-1.08 una diminuzione rispetto a rispetto a quello del 2022, che era di $-1.23.
Storico EPS per Tango Therapeutics, Inc. da 2019 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
2026 (TTM) $-0.85 -28.57%
2024 $-1.19 10.19%
2023 $-1.08 -12.20%
2022 $-1.23 30.85%
2021 $-0.94 -41.98%
2020 $-1.62 3.18%
2019 $-1.57 0.00%
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -2,137.65%
US
$-7.98 838.82%
US
$-5.29 522.35%
AU
- -
CH
$27.74 -3,363.53%
NL